Axsome Therapeutics AXSM EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's EPS (diluted)?
- Axsome Therapeutics (AXSM) reported EPS (diluted) of -$1.26 in Q1 2026.
- How has Axsome Therapeutics's EPS (diluted) changed year-over-year?
- Axsome Therapeutics's EPS (diluted) decreased by 3.3% year-over-year, from -$1.22 to -$1.26.
- What is the long-term trend for Axsome Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Axsome Therapeutics's EPS (diluted) has grown at a 1.5% compound annual growth rate (CAGR), from -$3.47 to -$3.68.
- What does EPS (diluted) mean?
- The profit per share assuming all potential shares are issued.
- How do you interpret EPS (diluted)?
- A smaller gap between basic and diluted EPS suggests lower potential dilution for existing shareholders.
- How does EPS (diluted) compare across companies?
- Standard metric for assessing the impact of equity-based compensation and convertible instruments on shareholder value.